Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$19.62 USD
+1.57 (8.70%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $19.72 +0.10 (0.51%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Arcturus Therapeutics Holdings Inc.'s return on equity, or ROE, is -24.87% compared to the ROE of the Medical - Biomedical and Genetics industry of -67.20%. While this shows that ARCT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ARCT 19.62 +1.57(8.70%)
Will ARCT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates
Other News for ARCT
Cathie Wood Pours $49M into Brera Holdings, Trims Roku and Tempus AI Stakes
Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225%
Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225%
ARCT forms Bollinger Band Squeeze on September 18
Cathie Wood Invests $37M into Biotech Stocks, Trims Stake in KTOS, TEM, and ROKU Stocks